The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Rates of primary prophylaxis for venous thromboembolism in high-risk patients with pancreatic and gastric cancer: A single tertiary care academic center experience.
 
Karlyn Martin
Research Funding - Janssen
 
Rebecca Molsberry
No Relationships to Disclose
 
Sadiya S Khan
No Relationships to Disclose
 
Al Bowen Benson
Consulting or Advisory Role - Astellas Pharma; AXIO Research; Bayer; Bristol-Myers Squibb; Exelixis; Genentech/Roche; Guardant Health; inVentiv Health; Lilly; LSK BioPharma; Merck; NCCN; Purdue Pharma; Rafael Pharmaceuticals; Terumo; TheraBionic
Research Funding - Acerta Pharma; advanced accelerator applications (Inst); Bristol-Myers Squibb; Celgene; Infinity Pharmaceuticals (Inst); MedImmune; Merck Sharp & Dohme (Inst); Novartis (Inst); Taiho Pharmaceutical (Inst); Xencor
Travel, Accommodations, Expenses - Astellas Pharma; AVEO; Bayer; Boehringer Ingelheim; Boston Biomedical; Bristol-Myers Squibb; Dava Oncology; Genentech/Roche; Gilead Sciences; Guardant Health; guerbet; Helsinn Healthcare; Lilly/ImClone; Sanofi; Spectrum Pharmaceuticals; TRM Oncology